State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Hua Xi Kou Qiang Yi Xue Za Zhi. 2021 Dec 1;39(6):690-697. doi: 10.7518/hxkq.2021.06.010.
This study was performed to investigate the effects of hyperbaric oxygen and other approaches for treating the osteoradionecrosis of the jaws (ORNJ) systematically.
According to the preset inclusion and exclusion criteria, randomized controlled trials and cohort studies on hyperbaric oxygen in the treatment of ORNJ were screened, and foreign language databases such as PubMed, EMBASE, and Cochrane library were searched via a computer; Chinese databases such as CNKI, VIP, Wanfang data, and CBM were searched from the established database to September 2020. Relevant books were searched manually to collect all literatures on the efficacy of hyperbaric oxygen and its related therapies in ORNJ treatment. Two researchers were independent and mutually blind, the papers were selected, data were collected, and the bias risk was evaluated. If any difference was detected, it would be decided by discussion or arbitrated by a third party. The data related to the efficacy of hyperbaric oxygen and its related therapy in the treatment of the ORNJ were extracted, and the Revman5.4 software was used for Meta-analysis. In case of large heterogeneity, sensitivity analysis was performed. A funnel chart was used to evaluate possible publication bias qualitatively.
Four randomized controlled trials and seven cohort studies were included in Meta-analyses. In ORNJ treatment, no significant differences between the group subjected to hyperbaric oxygen and both surgery and antibiotics and the group that underwent both surgery and antibiotics (RR=1.16, 95%CI: 0.861.58, >0.05); between the group with hyperbaric oxygen and the group with antibiotics (RR=0.83, 95%CI: 0.631.09, >0.05); between the group with hyperbaric oxygen and the group with antifibrotic drugs (RR=0.07, 95%CI: 0.00155.86, >0.05); between the group with single or combined use of HBO and the group with other intervention methods (RR=0.89, 95%CI: 0.671.19, >0.05).
Hyperbaric oxygen therapy cannot replace surgery and antibiotic therapy. Hyperbaric oxygen therapy is not superior to antibiotics and antifibrotic drugs, but the benefits of antifibrotic drugs should be further explored.
本研究旨在系统地研究高压氧和其他方法治疗颌骨放射性骨坏死(ORNJ)的效果。
根据预设的纳入和排除标准,筛选了高压氧治疗 ORNJ 的随机对照试验和队列研究,并通过计算机检索了 PubMed、EMBASE 和 Cochrane 图书馆等外文数据库;从已建立的数据库中检索了中国的数据库,如中国知网、维普、万方数据和 CBM,以检索截至 2020 年 9 月的所有关于高压氧及其相关疗法治疗 ORNJ 疗效的文献。手动检索相关书籍,以收集所有关于高压氧及其相关疗法治疗 ORNJ 疗效的文献。由两名研究人员独立且相互盲法筛选文献、收集数据并评估偏倚风险。如果发现任何差异,则通过讨论或第三方仲裁来决定。提取与高压氧及其相关疗法治疗 ORNJ 疗效相关的数据,并使用 RevMan5.4 软件进行 Meta 分析。如果存在较大的异质性,则进行敏感性分析。使用漏斗图定性评估可能存在的发表偏倚。
纳入 4 项随机对照试验和 7 项队列研究进行 Meta 分析。在 ORNJ 治疗中,高压氧组与手术和抗生素组以及手术和抗生素组之间无显著差异(RR=1.16,95%CI:0.861.58,>0.05);高压氧组与抗生素组之间(RR=0.83,95%CI:0.631.09,>0.05);高压氧组与抗纤维化药物组之间(RR=0.07,95%CI:0.00155.86,>0.05);单一或联合使用 HBO 组与其他干预措施组之间(RR=0.89,95%CI:0.671.19,>0.05)。
高压氧治疗不能替代手术和抗生素治疗。高压氧治疗并不优于抗生素和抗纤维化药物,但应进一步探索抗纤维化药物的益处。